Myriad Genetics Appoints Ben R. Wheeler as CFO

Myriad Genetics ( (MYGN) ) has issued an announcement.

On August 18, 2025, Myriad Genetics announced the appointment of Ben R. Wheeler as the new Chief Financial Officer, effective August 16, 2025, following the departure of Scott J. Leffler from the role. Wheeler, who has been with the company for over 13 years, brings extensive financial expertise and leadership experience, which is expected to support Myriad’s growth strategy. The company also reaffirmed its financial guidance for the full year 2025, indicating confidence in its strategic direction.

The most recent analyst rating on (MYGN) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.

Spark’s Take on MYGN Stock

According to Spark, TipRanks’ AI Analyst, MYGN is a Neutral.

Myriad Genetics’ overall stock score reflects strong revenue growth and strategic initiatives, such as the new credit agreement, which provide financial flexibility. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The positive momentum in technical analysis and raised guidance from the earnings call offer some optimism, but the stock remains under pressure due to fundamental weaknesses.

To see Spark’s full report on MYGN stock, click here.

More about Myriad Genetics

Myriad Genetics is a leading company in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being. The company develops and offers molecular tests that assess disease risk and guide treatment decisions across medical specialties, aiming to improve patient care and reduce healthcare costs.

Average Trading Volume: 1,985,638

Technical Sentiment Signal: Sell

Current Market Cap: $531.3M

For detailed information about MYGN stock, go to TipRanks’ Stock Analysis page.